담도폐쇄증 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 약물별, 병기별, 투여 경로별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Biliary Atresia Treatment Market size was valued at USD 1.1 billion in 2024 and is poised to grow from USD 1.17 billion in 2025 to USD 1.99 billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The Global Biliary Atresia Treatment Market encompasses therapeutic drugs, surgical techniques, and diagnostic services addressing a rare neonatal liver disorder known for causing progressive cholestasis and substantial morbidity. The urgency for effective treatments is propelled by high mortality rates, prompting early interventions like Kasai porto-enterostomy and promising gene therapy trials. Orphan-drug incentives stimulate market growth by encouraging the development of therapies for this condition affecting fewer than 200,000 infants, leading to advancements like adeno-associated viral vector platforms for enhancing bile flow. Furthermore, artificial intelligence is revolutionizing treatment approaches through improved detection, expedited drug development, and personalized patient care. Machine learning optimizes diagnostic imaging, while predictive analytics enable tailored surgical timing, collectively enhancing outcomes, reducing costs, and ensuring sustained market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biliary Atresia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biliary Atresia Treatment Market Segments Analysis

The global biliary atresia treatment market is segmented by treatment type, drug type, disease stage, route of administration, application, end user, distribution channel and region. Based on treatment type, the market is segmented into Kasai Portoenterostomy, Liver Transplantation, Drug Therapy and Supportive & Nutritional Care. Based on drug type, the market is segmented into Ursodeoxycholic Acid (UDCA), Antibiotics, Fat-Soluble Vitamin Supplements and Others. Based on disease stage, the market is segmented into Early-Stage Biliary Atresia and Advanced Biliary Atresia. Based on route of administration, the market is segmented into Oral and Injectable. Based on application, the market is segmented into Bile Flow Restoration, Liver Function Management, Nutritional Support and Post-Transplant Care. Based on end user, the market is segmented into Hospitals, Pediatric Specialty Centers, Liver Transplant Centers and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biliary Atresia Treatment Market

The emergence of minimally invasive techniques, along with advancements in the Kasai portoenterostomy procedure, significantly reduces postoperative complications, shortens hospital stays, and enhances liver function in patients. This encourages early intervention by healthcare professionals, expanding the eligible patient population for treatment. As a result, the demand for specialized devices and skilled treatment centers increases, driving market growth as more facilities adopt innovative surgical solutions. Additionally, the integration of intraoperative imaging and real-time monitoring contributes to more accurate biliary reconstruction, decreasing the likelihood of revisions and improving patient outcomes. This fosters stronger reimbursement support and accelerates market expansion both locally and globally.

Restraints in the Global Biliary Atresia Treatment Market

The limited availability of suitable donor livers for transplantation presents a significant challenge in the Global Biliary Atresia Treatment market, restricting the number of patients who can access a definitive surgical cure. This scarcity leads to a constrained demand for transplant-related technologies and services, as allocation policies often prioritize urgent cases, resulting in prolonged waiting times for many candidates. Such delays dampen enthusiasm for products associated with the transplant pathway, ultimately hindering market momentum. Consequently, there is a greater reliance on palliative or interim therapy options, which do not significantly contribute to the growth of high-value market segments.

Market Trends of the Global Biliary Atresia Treatment Market

The Global Biliary Atresia Treatment market is currently experiencing a notable shift towards the integration of targeted molecular therapies, which aim to address the underlying pathophysiology rather than relying solely on surgical interventions. By leveraging advancements in genomics and proteomics, researchers are developing innovative agents that not only mitigate fibrosis and inflammation but also promote bile duct regeneration. This trend highlights the growing emphasis on precision medicine, leading to collaborations between biotechnology companies and pediatric hepatology centers that enhance clinical trial pipelines. As a result, the market is expected to expand therapeutic options and improve long-term outcomes for children diagnosed with biliary atresia worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology

Global Biliary Atresia Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Kasai Portoenterostomy
• Liver Transplantation
• Drug Therapy
• Supportive & Nutritional Care

Global Biliary Atresia Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Ursodeoxycholic Acid (UDCA)
• Antibiotics
• Fat-Soluble Vitamin Supplements
• Others

Global Biliary Atresia Treatment Market Size by Disease Stage & CAGR (2026-2033)

• Market Overview
• Early-Stage Biliary Atresia
• Advanced Biliary Atresia

Global Biliary Atresia Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Biliary Atresia Treatment Market Size by Application & CAGR (2026-2033)

• Market Overview
• Bile Flow Restoration
• Liver Function Management
• Nutritional Support
• Post-Transplant Care

Global Biliary Atresia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Pediatric Specialty Centers
• Liver Transplant Centers
• Ambulatory Care Centers

Global Biliary Atresia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Biliary Atresia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mirum Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivet Therapeutics SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Generation Bio Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abeona Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rectify Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albireo Pharma (Ipsen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ann & Robert H. Lurie Children's Hospital Research Programs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Children's Hospital Research Programs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Children's Hospital of Philadelphia Research Programs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• King's College London Liver Research Program
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations